Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 3/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19730390 | 0.95 | TSPO (0.47) | TSPO | |
| SCHEMBL19730397 | 0.89 | SLC2A2 (0.55) | TSPO | |
| SCHEMBL19730396 | 0.89 | TSPO (0.50) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL19730394 | 0.85 | TP53 (0.41) | TSPOCYP3A4 | |
| SCHEMBL19730391 | 0.85 | — | — | |
| SCHEMBL19730393 | 0.79 | TSPO (0.52) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL19730398 | 0.78 | GABRA2 (0.49) | TSPO | |
| SCHEMBL19738665 | 0.78 | SLC2A2 (0.51) | TSPOLMNA | |
| SCHEMBL19730389 | 0.74 | GABRA2 (0.51) | TSPO | |
| Alpdem SCHEMBL1230701 | 0.70 | TSPO (1.00) | TSPOGMNNLMNAPOLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202376-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202376-B2 | Heterocyclic compound | GRIN2A, GRIN1, GRIN2B | TSPO 392/4885GMNN 3056/4885LMNA 3379/4885 |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | GRIN2A, GRIN1, GRIN2B | TSPO 392/4885GMNN 3056/4885LMNA 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.